Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400539 | 1.00 | MAOB (0.58) | MAOBTOP1CA1CA2ARG2 | |
| SCHEMBL5543802 | 0.81 | KCNH2 (0.39) | MAOBIDO1KCNH2AGXT | |
| SCHEMBL5539392 | 0.81 | MAOB (0.54) | MAOBTOP1CA1CA2ARG2 | |
| SCHEMBL5535337 | 0.81 | GPR52 (0.45) | — | |
| SCHEMBL5535334 | 0.81 | GPR52 (0.45) | — | |
| SCHEMBL5543799 | 0.81 | KCNH2 (0.39) | MAOBIDO1KCNH2AGXT | |
| SCHEMBL5539395 | 0.81 | MAOB (0.54) | MAOBTOP1CA1CA2ARG2 | |
| SCHEMBL5541407 | 0.79 | TOP1 (0.53) | MAOBTOP1CA1CA2ARG2 | |
| SCHEMBL5541411 | 0.79 | TOP1 (0.53) | MAOBTOP1CA1CA2ARG2 | |
| SCHEMBL5513084 | 0.77 | MAOB (0.71) | MAOBTOP1CA1CA2ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | MITSUI CHEMICALS, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-7405030-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2008-07-29 | — | — | US | disclosed |
| EP-1930339-A2 | Imide compound | MITSUI CHEMICALS, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20070259151-A1 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7259260-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-08-21 | — | — | US | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1180765-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS INC (JP) | 2005-04-06 | — | — | EP | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1445115-A1 | IMIDE COMPOUNDS AND OPTICAL RECORDING MEDIA MADE BY USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20030194646-A1 | Mono-, di-, and triazaporphyrin compounds optionally in the form of a metal or metalloid complex | MITSUI CHEMICALS, INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | CACNA1B, KCNN4, KCNN2 | MAOB 441/4885TOP1 3546/4885CA1 174/4885 |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | MAOB 113/4885TOP1 3520/4885CA1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.